Claims
- 1. A compound of Formula I: ##STR63## wherein the bonds between C.sub.2 and C.sub.3 and/or between C.sub.4 and C.sub.5 are unsaturated;
- X=COOH, H, F, C.sub.1, Br, I, COOR", CONH.sub.2, COR"', CHO, CH.sub.2 OH, CH.sub.2 OR"', OH, OR"', CF.sub.3, C.sub.1-6 alkyl, C.sub.1-6 alkenyl, C.sub.1-6 haloalkyl, NO.sub.2, P(O)(OH).sub.2, SO.sub.2 H, or SO.sub.3 H;
- R=substituted or unsubstituted alkyl, aryl, arylalkyl, alkenyl, or arylalkenyl groups, with the proviso that each of these groups must have 6 or more carbons and R cannot be ##STR64## R'=H or C.sub.1-6 alkyl; R"=H, C.sub.1-6 alkyl, C(R.sup.3).sub.2 OC(O)R.sup.4, CH.sub.2 CH.sub.2 NR.sup.5 R.sup.6, CH.sub.2 CH.sub.2 CH.sub.2 NR.sup.5 R.sup.6,
- CH.sub.2 C(O)N(R.sup.6).sub.2, or other groups yielding physiologically hydrolyzable esters;
- R"'=C.sub.1-6 alkyl;
- R.sup.3 =H, CH.sub.3, C.sub.2 H.sub.5, CH.sub.3 CH.sub.2 CH.sub.2 (with R.sup.3 's being the same or different);
- R.sup.4 =C.sub.6-12 aryl, C.sub.1-7 linear, branched or cyclic alkyl, or C.sub.1-7 linear, branched or cyclic alkoxy;
- R.sup.5 =R.sup.6, or when linked with R.sup.6, is a C.sub.3 -C.sub.6 cycloalkyl or a --CH.sub.2 CH.sub.2 OCH.sub.2 CH.sub.2 -group; and
- R.sup.6 =C.sub.1-3 alkyl.
- 2. The compounds of claim 1 having a structure selected from the group consisting of structure types IA, IB, IC, and ID: ##STR65##
- 3. The compound of claim 2 conforming to structure IA.
- 4. The compound of claim 3 selected from the group consisting of:
- (2Z), (4Z)-4-(3-carboxyphenyl)-5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2,4-pentadienoic acid;
- (2Z), (4Z)-4-(3-carboxyphenyl)-5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)-2,4-pentadienoic acid;
- (2Z), (4Z)-4-(3-carboxyphenyl)-5-(4-decyloxyphenyl)-2,4-pentadienoic acid;
- (2Z), (4Z)-4-(3-carboxyphenyl)-5-(3,4-bisdecyloxyphenyl)-2,4-pentadienoic acid;
- (2Z), (4Z)-4-(3-carboxyphenyl)-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2,4-heptadienoic acid;
- (2Z), (4Z), (6E)-4-(3-carboxyphenyl)-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2,4,6-octatrienoic acid;
- (2Z), (4Z)-4-(3-carboxyphenyl)-7-[4-(1-adamantyl)-3-methoxyphenyl]-2,4-heptadienoic acid;
- (2Z), (4Z)-4-(3-carboxyphenyl)-7-[3-(1-adamantyl)-4-methoxyphenyl]-2,4-heptadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-5-(4-decyloxyphenyl]-2,4-pentadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-5-(3-decyloxyphenyl]-2,4-pentadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-5-(2-decyloxyphenyl]-2,4-pentadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-5-[4-(2E), (6E)-3,7-dimethylocta-2,6-dienoxy]phenyl-2,4-pentadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-5-(3,4-bisdecyloxyphenyl)-2,4-pentadienoic acid;
- (2E), (4Z)-4-(3-trifluoromethylphenyl)-5-(3,4-bisdecyloxyphenyl)-2,4-pentadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)-2,4-pentadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2,4-heptadienoic acid;
- (2Z), (4Z)-4-(4-fluorophenyl)-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2,4-heptadienoic acid;
- (2Z), (4Z)-4-(3-fluorophenyl)-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2,4-heptadienoic acid;
- (2Z), (4Z)-4-phenyl-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2,4-heptadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-7-[3-(1-adamantyl )-4-methoxyphenyl]-2,4-heptadienoic acid;
- (2Z), (4Z)-4-phenyl-7-[3-(1-adamantyl)-4-methoxyphenyl]-2,4-heptadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-7-[4-(1-adamantyl)-3methoxyphenyl]-2,4-heptadienoic acid;
- (2Z), (4Z)-4-phenyl-7-[4-(1-adamantyl)-3-methoxyphenyl]-2,4-heptadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-7-[2-(1-adamantyl)-4-methoxyphenyl]-2,4-heptadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-5-[4-(1-adamantyl)-3-methoxyphenyl]-2,4-pentadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-7-[4-(1-adamantyl)-3-hydroxyphenyl]-2,4-heptadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-7-[4-(1-adamantyl)-3-pentyloxyphenyl]-2,4-heptadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-7-[4-(1-adamantyl)-3-(4-methoxybenzyloxy)phenyl]-2,4-heptadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-7-[4-(1-adamantyl)-3-benzyloxy)phenyl]-2,4-heptadienoic acid;
- (2Z), (4Z)-4-(3-trifluoromethylphenyl)-7-[4-(1-adamantyl)-3-(carboxymethoxy)phenyl]-2,4-heptadienoic acid; and
- (2Z), (4Z)-3-methyl-4-(3-carboxyphenyl)-5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)-2,4-pentadienoic acid;
- 5. The compound of claim 2 conforming to structure IB.
- 6. The compound of claim 5 selected from the group consisting of:
- (2E), (4Z)-4-(3-carboxyphenyl)-5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)-2,4-pentadienoic acid;
- (2E), (4Z)-4-(3-carboxyphenyl)-5-(3,4-bispentyloxyphenyl)-2,4-pentadienoic acid;
- (2E), (4Z)-4-(3-carboxyphenyl)-5-(3,4-bisdecyloxyphenyl)-2,4-pentadienoic acid;
- (2E), (4Z)-4-(3-carboxyphenyl)-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2,4-heptadienoic acid;
- (2E), (4Z)-4-(3-trifluoromethylphenyl)-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2,4-heptadienoic acid;
- (2E), (4Z)-4-(4-fluorophenyl)-7-(5,6,7,8-tetrahydro-5,5,8,8tetramethyl-2-naphthalenyl)-2,4-heptadienoic acid;
- (2E), (4Z)-4-(3-fluorophenyl)-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2,4-heptadienoic acid;
- (2E), (4Z)-4-phenyl-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2,4-heptadienoic acid;
- (2E), (4Z)-4-(3-trifluoromethylphenyl)-7-[3-(1-adamantyl)-4-methoxyphenyl]-2,4-heptadienoic acid; and
- (2E), (4Z)-4-(3-trifluoromethylphenyl)-7-[4-(1-adamantyl)-3-methoxyphenyl]-2,4-heptadienoic acid;
- 7. The compound of claim 2 conforming to structure IC.
- 8. The compound of claim 7 selected from the group consisting of:
- (2E), (6E)-4-(3-carboxyphenyl)-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2,6-octadienoic acid, and
- (2E)-4-[3-carboxyphenyl]-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-hepta-2-enoic acid.
- 9. The compound of claim 2 conforming to structure ID.
- 10. (Z)-4-(3-trifluoromethylphenyl)-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-4-heptenoic acid.
- 11. A potassium, sodium, triethanolamine, tris(hydroxymethyl)aminomethane, N-methylglucamine, or L-lysine monosalt of a compound of claim 1 in which R"=H.
- 12. A potassium, sodium, triethanolamine, tris(hydroxymethyl)aminomethane, N-methylglucamine, or L-lysine bissalt of a compound of claim 1 in which R"=H and X=COOH.
- 13. The dipotassium salt of (2Z), (4Z)-3-methyl-4-(3carboxyphenyl)-5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)-2,4-pentadienoic acid.
- 14. The disodium salt of (2Z), (4Z)-3-methyl-4-(3-carboxyphenyl)-5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)-2,4-pentadienoic acid.
- 15. The bis(triethanolamine) salt of (2Z), (4Z)-3-methyl-4-(3-carboxyphenyl)-5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)-2,4-pentadienoic acid.
- 16. The bis-[tris(hydroxymethyl)aminomethane] salt of (2Z), (4Z)-3-methyl-4-(3-carboxyphenyl)-5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)-2,4-pentadienoic acid.
- 17. The bis-(N-methylglucamine) salt of (2Z), (4Z)-3-methyl-4-(3carboxyphenyl)-5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)-2,4-pentadienoic acid.
- 18. The bis-(L-lysine) salt of (2Z), (4Z)-3-methyl-4-(3-carboxyphenyl)-5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)-2,4-pentadienoic acid.
- 19. The method of making a compound of structure type IA comprising the step: ##STR66## wherein reaction takes place at about 0.degree. C. in the presence of an organic diluent.
- 20. A pharmaceutical composition containing an anti-inflammatory effective amount of at least one compound of claim 1 and a suitable amount of at least one pharmaceutically acceptable carrier.
- 21. The composition of claim 20 wherein the compound of claim 1 is present in an amount of about 0.005 to about 10.0 wt %.
- 22. The composition of claim 21 in a topical dosage form.
- 23. The composition of claim 21 in an oral dosage form.
- 24. A method of treating inflammation comprising the step of administering to a subject an anti-inflammatory effective amount of a compound of claim 1.
- 25. A method of treating inflammation comprising the step of administering to a subject an anti-inflammatory effective amount of a compound of claim 2.
- 26. The method of claim 25 wherein the compound is administered via a topical formulation.
- 27. The method of claim 25 wherein the compound is administered via an oral formulation.
- 28. The method of claim 19 wherein the reaction takes place in the presence of tetrahydrofuran.
CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of application Ser. No. 08/079,072, filed Jun. 16, 1993, abandoned.
Non-Patent Literature Citations (1)
Entry |
Chem-Abs 88(7):50605 p 1978. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
79072 |
Jun 1993 |
|